- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
A company is advancing an AI diagnostic solution through FDA clearance and establishing a local base in Boston.
3 reports, 3 independent
Updated May 26
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company is advancing an AI diagnostic solution through FDA clearance and establishing a local base in Boston.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
National IT Industry Promotion Agency
governmental IT industry promotion organization in South Korea
Nothing else this week.
-
Korea Health Industry Development Institute
government organization in Seoul, South Korea
Nothing else this week.
Related events
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- Immuneering submitted a meeting request to the FDA regarding its therapies.
- A study author is based in Johns Hopkins School of Medicine, and the research is connected to Baltimore, now involving the FDA for drug approval.
Coverage
Newest first; wire copies grouped- sleepreviewmag.com
- GuruFocus.comHyperfine Inc (HYPR) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions ... Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the f
- GlobeNewswireDeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™ TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultr